PD0332991 HCl , ≥98% , 827022-32-2
Synonym(s):
6-Acetyl-8-cyclopentyl-5-methyl-2-(5-(piperazin-1-yl)pyridin-2-ylamino)pyrido[2,3-d]pyrimidin-7(8H)-one, HCl, Cdk4/Cdk6 Inhibitor V, PD-0332991, HCl, PF-332991, HCl;StemSelect PD 0332991 - CAS 827022-32-2 - Calbiochem
CAS NO.:827022-32-2
Empirical Formula: C24H30ClN7O2
Molecular Weight: 483.994
MDL number: MFCD22420809
EINECS: 1592732-453-0
Pack Size | Price | Stock | Quantity |
5MG | RMB239.20 | In Stock |
|
10MG | RMB375.20 | In Stock |
|
50MG | RMB1119.20 | In Stock |
|
100MG | RMB1599.20 | In Stock |
|
250mg | RMB2799.20 | In Stock |
|
others | Enquire |
PRODUCT Properties
storage temp. | = -70C |
solubility | ≥14.48 mg/mL in H2O; ≥2.42 mg/mL in DMSO; ≥2.79 mg/mL in EtOH with gentle warming and ultrasonic |
form | Yellow liquid |
color | Light yellow to yellow |
Description and Uses
PD 0332991 is an orally active, selective inhibitor of the cyclin D kinases Cdk4 (IC50 = 11 nM) and Cdk6 (IC50= 16 nM) with no activity against a panel of 36 additional protein kinases. It has been reported to have antiproliferative activity against retinoblastoma-positive tumor cells, blocking retinoblastoma phosphorylation and inducing G1 arrest at nanomolar concentrations. PD 0332991 can inhibit the growth of certain ER-positive or HER2-amplified breast cancer cells (IC50s as low as 4 nM) and demonstrates synergy with tamoxifen and trastuzumab, respectively. PD 0332991 inhibition of Cdk4 activity has been used to demonstrate a role for insulin-activated cyclinD1-Cdk4 signaling in the control of glucose metabolism that is independent of cell cycle progression.
Safety
Symbol(GHS) | GHS07 |
Signal word | Warning |
Hazard statements | H315-H319 |
Precautionary statements | P264-P280-P302+P352-P337+P313-P305+P351+P338-P362+P364-P332+P313 |
HS Code | 29399990 |